TMCnet News
Obesity Pipeline Review, H1 2017 - Therapeutics Report on 96 Companies & Drug Profiles - Research and MarketsResearch and Markets has announced the addition of the "Obesity - Pipeline Review, H1 2017" report to their offering. Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively. Obesity (Metaolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
Companies Mentioned
For more information about this report visit http://www.researchandmarkets.com/research/t4k8ct/obesity View source version on businesswire.com: http://www.businesswire.com/news/home/20170525005784/en/ |
